Loading
A phase 3 trial testing Bomedemstat in myeloproliferative neoplasms, now recruiting.
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) is a phase 3 interventional study registered as NCT06351631, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study. Planned enrolment is 400 participants (estimated). The study started in 2024-05-23 and primary completion is expected in 2034-12-04. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/